130 related articles for article (PubMed ID: 810919)
1. Treatment of multiple myeloma and macroglobulinemai Waldenström: A long-term follow-up study.
Onodera S; Otaki M; Oikawa K; Mikami M; Sato I
Tohoku J Exp Med; 1975 Aug; 116(4):317-25. PubMed ID: 810919
[TBL] [Abstract][Full Text] [Related]
2. The chemotherapy of plasma cell myeloma and related disorders.
Coleman M; Silver RT
Antibiot Chemother (1971); 1974; 18():112-47. PubMed ID: 4219116
[No Abstract] [Full Text] [Related]
3. [Treatment of Kahler's disease].
Foa J; Carcassonne Y
Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
[No Abstract] [Full Text] [Related]
4. [Therapy of malignant gammopathies].
Emmerich B
Dtsch Med Wochenschr; 1984 Jan; 109(1):26-30. PubMed ID: 6420138
[No Abstract] [Full Text] [Related]
5. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
[TBL] [Abstract][Full Text] [Related]
6. [Trial of combination chemotherapy for multiple myeloma and macroglobulinemia--VENAP therapy (author's transl)].
Furukawa K; Fujiwara Y; Nakaide Y; Tanaka M; Tanaka M; Hirota Y
Rinsho Ketsueki; 1980 Nov; 21(11):1683-91. PubMed ID: 6782278
[No Abstract] [Full Text] [Related]
7. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
8. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.
Ghobrial IM; Vij R; Siegel D; Badros A; Kaufman J; Raje N; Jakubowiak A; Savona MR; Obreja M; Berdeja JG
Clin Cancer Res; 2019 Aug; 25(16):4907-4916. PubMed ID: 31142508
[TBL] [Abstract][Full Text] [Related]
9. Steroid therapy of multiple myeloma and macroglobulinemia.
Hoogstraten B
Med Clin North Am; 1973 Sep; 57(5):1321-30. PubMed ID: 4366516
[No Abstract] [Full Text] [Related]
10. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
[No Abstract] [Full Text] [Related]
11. Combination chemotherapy (M-2) protocol (BCNU, cyclophosphamide, vincristine, melphalan, and prednisone) for Waldenström macroglobulinemia: preliminary report.
Case DC
Blood; 1982 May; 59(5):934-7. PubMed ID: 6803856
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of multiple myeloma. Review of the recent trials].
Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
[No Abstract] [Full Text] [Related]
13. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Case DC; Lee DJ; Clarkson BD
Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
[No Abstract] [Full Text] [Related]
14. [Clinical experience on the use of l-phenylalanin nitrogen mustard (melphalan)].
Artigas L; Dondo Lascano F; Seoane MR; Sagasta C
Prensa Med Argent; 1970 Mar; 57(3):142-8. PubMed ID: 4989273
[No Abstract] [Full Text] [Related]
15. [Benign and malignant monoclonal hypergammaglobulinemia (gammopathy)].
Waldenström J
Schweiz Med Wochenschr; 1970 Feb; 100(7):290-6. PubMed ID: 4189916
[No Abstract] [Full Text] [Related]
16. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
17. Blood and neoplastic diseases. Myelomatosis.
Malpas JS
Br Med J; 1974 Nov; 4(5943):520-2. PubMed ID: 4434121
[No Abstract] [Full Text] [Related]
18. Letter: Treatment of myeloma.
Jacobs P; Dubovsky D
Br Med J; 1975 Mar; 1(5958):625. PubMed ID: 1125634
[No Abstract] [Full Text] [Related]
19. [Therapy of Waldenstrom's disease and of heavy chain disease].
Schubert JC
Hamatol Bluttransfus; 1976; 18():401-17. PubMed ID: 823079
[No Abstract] [Full Text] [Related]
20. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
Bergsagel DE; Cowan DH; Hasselback R
Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
